Continuous Manufacturing: A Practical
Continuous manufacturing will find the greatest success with
organizations taking a platform approach, according to Eric Jayjock,
Director of Continuous Manufacturing at Patheon.
By Meg La Torre-Snyder, Editor
Over the last 50 years, continuous manufacturing technologies have been slow to advance, remaining relatively unchanged. However, there has
been an uptick in recent years in the dialogue
surrounding continuous manufacturing and its
potential applicability in the pharmaceutical and
At the forefront, the U.S. Food and Drug
Administration (FDA) now encourages
companies to incorporate continuous
manufacturing into their processes, stating it has
a strong impact on drug quality.
“We know that the FDA, which has been
encouraging industry adoption of new
manufacturing technologies as a means to
improve and ensure quality, is a strong advocate
of continuous manufacturing,” said Eric
Jayjock, Director of Continuous Manufacturing
at Patheon, a contract development and
manufacturing organization (CDMO).
In April of 2016, the FDA approved Johnson
& Johnson’s switch from batch to continuous
manufacturing for the production of Prezista,
a drug used to treat HIV. Since that time,
continuous manufacturing and continuous
processing are buzz words on everyone’s lips.
“I think an increasing number of companies
will continue to explore continuous
manufacturing as an option,” said Jayjock.
Calling continuous manufacturing “
game-changing,” Jayjock further explained that, on the
development side, it has the potential to develop
new products using a smaller quantity of active
pharmaceutical ingredients (APIs).
“Once we are manufacturing in real time, the
data-rich nature of this technology will enable us